MCRB
Seres Therapeutics, Inc. · Healthcare
No insider bought or sold Seres Therapeutics, Inc. in the last 12 months
MCRB over the last year
MCRB after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
53 insider filings since 2016, newest first
Teresa L. Young · Insider
David S. Ege · Insider
David S. Ege · Insider
Nutritional Health Ltp Fund General Partner LLC · 10% owner
Matthew R. Henn · Insider
Noubar Afeyan · Director and 10% owner
Thomas Desrosier · General Counsel and EVP
Eric D. Shaff · Insider
John G. Aunins · CTO and EVP
John G. Aunins · Insider
John G. Aunins · Insider
John G. Aunins · Insider
Roger Pomerantz · President and CEO
John G. Aunins · CTO and EVP
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
John G. Aunins · CTO and EVP
John G. Aunins · CTO and EVP
Eric D. Shaff · Insider
Thomas Desrosier · Insider
Michele Trucksis · Insider
John G. Aunins · CTO and EVP
John G. Aunins · CTO and EVP
John G. Aunins · CTO and EVP
Michele Trucksis · Chief Medical Officer and EVP
Roger Pomerantz · President and CEO
Michele Trucksis · Chief Medical Officer and EVP
John G. Aunins · CTO and EVP
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Eric D. Shaff · CFO and EVP
John G. Aunins · CTO and EVP
Eric D. Shaff · CFO and EVP
Roger Pomerantz · President and CEO
David N Cook · Chief Scientific Officer and EVP
Roger Pomerantz · President and CEO
David N Cook · Chief Scientific Officer and EVP
John G. Aunins · CTO and EVP
Noubar Afeyan · Director and 10% owner
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
Roger Pomerantz · President and CEO
David N Cook · Chief Scientific Officer and EVP
Eric D. Shaff · CFO and EVP
Roger Pomerantz · President and CEO
David N Cook · Chief Scientific Officer and EVP
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.